Related Experiment Videos
Ocular manifestations of systemic malignancies
S D Solomon1, J H Smith, J O'Brien
1Department of Ophthalmology, University of California, San Francisco, USA.
Current Opinion in Ophthalmology
|February 8, 2000
Summary
Ocular manifestations of systemic malignancy, like paraneoplastic retinopathy, can precede cancer diagnosis. Autoantibodies against tumor antigens cause vision loss by affecting retinal proteins.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Ocular manifestations of systemic malignancy are crucial for early cancer detection.
- Visual paraneoplastic syndromes can be the initial sign of underlying cancer.
Purpose of the Study:
- To review the clinical manifestations, etiology, and therapies for visual paraneoplastic syndromes.
- To discuss carcinoma-associated retinopathy and melanoma-associated retinopathy.
- To examine metastatic tumors to the eye.
Main Methods:
- Literature review of current research on ocular paraneoplastic syndromes.
- Analysis of clinical presentations and etiologies.
- Review of therapeutic interventions.
Main Results:
- Visual paraneoplastic syndromes involve autoantibodies against tumor antigens that cross-react with retinal proteins.
- These antibodies lead to rod and cone dysfunction.
- Metastatic tumors to the eye have varied presentations, origins, and distributions.
Conclusions:
- Ocular findings can be early indicators of systemic malignancy.
- Understanding these syndromes aids in timely diagnosis and management.
- Further research into therapeutic strategies is warranted.